Beam Therapeutics, Inc. BEAM
NASDAQ · United States · Health Technology
$24.80+0.41 (+1.66%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
In September 2026, Beam Therapeutics filed a lawsuit alleging that former scientist Zi Jun “Emma” Wang stole confidential research to co-found Chinese biotech YolTech Therapeutics and, through it, helped create Serapha Bio using Beam’s trade secrets and patentable know‑how. This dispute underscores intensifying concerns over intellectual property protection and cross‑border competition in gene editing, particularly between U.S. and Chinese biotech companies. We’ll now examine how this...
Beam claimed a former scientist stole confidential information and quietly spun up a rival rare disease treatment at YolTech Therapeutics. Serapha Bio, which licensed that therapy, denies the charges.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Here's how to play leading gene-editing stocks as Anthropic's AI tools make progress in the gene-editing space.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.